Just to add E&P apparently made a pitch to Acadia to consider a small trial of 2591 in Rett patients in Australia prior to a larger registrational trial in US.
I have long wondered why NEU haven't considered a phase 2 in Prader Willi Syndrome in Australia given they successfully ran the phase 2 Angelman trial out of Sydney, Brisbane and Melbourne and PWS has a very similar incidence to Angelman. I understand there is competition in the space in US but a phase 2 in Australia with small numbers would be relatively inexpensive and would surely add value in the extremely likely event it was positive.
NEU Price at posting:
$12.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)